Zydus Life board greenlights acquisition of 85.6% stake in Amplitude Surgical for €256.8 million

Zydus Life plans to initiate a tender offer to acquire the full stake after the acquisition.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

The board of Zydus Lifesciences, on March 11, approved the acquisition of an 85.6 percent stake in France-based Amplitude Surgical for a total of €256.8 million. The acquisition will be executed at a floor price of  €6.25 per share.

If the conditions of the tender offer are met, the Zydus Life plans to proceed with a compulsory acquisition of the remaining shares held by minority shareholders and subsequently delist Amplitude Surgical from Euronext Paris.

Following the completion of the mandatory tender offer, the company aims to acquire full ownership, controlling 100 percent of Amplitude Surgical’s equity shares. As of June 30, 2024, Amplitude Surgical reported a turnover of €106 million.

Founded in 1997 and headquartered in France, Amplitude Surgical specialises in high-quality lower-limb orthopedic products and solutions, with a strong presence across multiple geographies, including France, Brazil, Australia, Germany, Switzerland, Belgium, and South Africa. Backed by its extensive distribution network and commitment to high regulatory standards, the company has demonstrated consistent revenue growth over the years. As per the audited consolidated financial statements under IFRS, Amplitude Surgical reported revenues of €106.0 million in FY24, €100.2 million in FY23, and €87.6 million in FY22.

Amplitude Surgical holds a leading position in the highly attractive orthopedics market, with a global presence supported by an extensive distribution network. Its high-quality products meet the highest regulatory standards, and its reach is expected to expand further through an ongoing product development pipeline and computer-assisted programs.

The proposed acquisition will serve as a strategic platform to execute Zydus' global MedTech ambitions, acting as a natural extension of its proven expertise in life sciences and wellness. Additionally, this acquisition presents an opportunity to leverage Amplitude Surgical’s strengths in global markets.

"We believe this was a natural extension in the field of medical technology. Our commitment to quality excellence, continuous investments in R&D and expertise in manufacturing will guide our foray into highly specialised MedTech products, adding a new dimension to our operations. In Amplitude Surgical, we see several medium-term and long-term growth opportunities with respect to portfolio, capabilities, manufacturing and geographies,” Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, said in an exchange filing.